French oncology specialist Servier Pharmaceuticals announced on Friday that VORANIGO (vorasidenib) has been awarded The Galien Foundation's 2025 Prix Galien USA Award for Best Product for Orphan/Rare Disease.

This award was conferred in a ceremony at the American Museum of Natural History in New York on 30 October 2025.

VORANIGO is the first and only targeted treatment approved by the US Food and Drug Administration (FDA) to treat patients with Grade 2 glioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation. VORANIGO was granted Fast Track, Breakthrough and Orphan Drug Designations and was approved by the US FDA on 6 August 2024 under Priority Review.

David K Lee, Servier's executive vice president, USA, said: "We take great pride in the recognition of the groundbreaking scientific achievements that brought VORANIGO to thousands of patients living with glioma in the US. This award is an endorsement of Servier's innovative approach to drug development, as well as our patient-focused and values-driven identity. We're redrawing the pharmaceutical landscape and transforming our organisation into a global force in precision oncology guided by our belief that no disease is too challenging to address, and no patient population is too small to benefit."